These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Aldalimumab in psoriatic arthritis and as the initial therapy in rheumatoid arthritis]. Krankenpfl J; 2005; 43(7-10):244. PubMed ID: 16515313 [No Abstract] [Full Text] [Related]
23. Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Deyab G; Hokstad I; Whist JE; Småstuen MC; Agewall S; Lyberg T; Bottazzi B; Meroni PL; Leone R; Hjeltnes G; Hollan I PLoS One; 2017; 12(2):e0169830. PubMed ID: 28225768 [TBL] [Abstract][Full Text] [Related]
24. Golimumab. Pappas DA; Bathon JM; Hanicq D; Yasothan U; Kirkpatrick P Nat Rev Drug Discov; 2009 Sep; 8(9):695-6. PubMed ID: 19721444 [No Abstract] [Full Text] [Related]
25. Coexistence of ankylosing spondylitis and rheumatoid arthritis in a female patient. Baksay B; Dér A; Szekanecz Z; Szántó S; Kovács A Clin Rheumatol; 2011 Aug; 30(8):1119-22. PubMed ID: 21505766 [TBL] [Abstract][Full Text] [Related]
26. Discordance of Global Assessments by Patient and Physician Is Higher in Female than in Male Patients Regardless of the Physician's Sex: Data on Patients with Rheumatoid Arthritis, Axial Spondyloarthritis, and Psoriatic Arthritis from the DANBIO Registry. Lindström Egholm C; Krogh NS; Pincus T; Dreyer L; Ellingsen T; Glintborg B; Kowalski MR; Lorenzen T; Madsen OR; Nordin H; Rasmussen C; Hetland ML J Rheumatol; 2015 Oct; 42(10):1781-5. PubMed ID: 26233511 [TBL] [Abstract][Full Text] [Related]
27. Felty syndrome: a case report. Gupta A; Abrahimi A; Patel A J Med Case Rep; 2021 May; 15(1):273. PubMed ID: 34039422 [TBL] [Abstract][Full Text] [Related]
28. Liver disease, erroneously attributed to methotrexate, in a patient with rheumatoid arthritis. Bills LJ; Seibert D; Brick JE J Rheumatol; 1992 Dec; 19(12):1963-5. PubMed ID: 1294748 [TBL] [Abstract][Full Text] [Related]
29. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Huscher D; Merkesdal S; Thiele K; Zeidler H; Schneider M; Zink A; Ann Rheum Dis; 2006 Sep; 65(9):1175-83. PubMed ID: 16540552 [TBL] [Abstract][Full Text] [Related]
30. [Revision of the recommendations of the Commission on Pharmacotherapy of the German society for Rheumatology. Therapy with tumour necrosis factor blockers for inflammatory rheumatic illnesses]. Manger B; Michels H; Nüsslein HG; Schneider M; Sieper J; Z Rheumatol; 2007 Feb; 66(1):72-5. PubMed ID: 17221253 [TBL] [Abstract][Full Text] [Related]
31. [Comment on H. Kaiser: "Current aspects of SAPHO syndrome"]. Schilling F; Kaiser H Z Rheumatol; 1996; 55(1):71-2; author reply 75. PubMed ID: 8868154 [No Abstract] [Full Text] [Related]
32. [Clinical observations of a case of anterior uveitis associated with ankylosing spondylitis and psoriatic arthritis. Paraclinical studies]. Costescu I; Vîlciu A Oftalmologia; 1998; 42(2):74-7. PubMed ID: 9932362 [TBL] [Abstract][Full Text] [Related]
33. Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides. Biggioggero M; Favalli EG Drug Dev Res; 2014 Nov; 75 Suppl 1():S38-41. PubMed ID: 25381973 [TBL] [Abstract][Full Text] [Related]
34. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260 [No Abstract] [Full Text] [Related]
35. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191 [TBL] [Abstract][Full Text] [Related]
36. [Two faces of an illness: rheumatoid arthritis followed by ankylosing spondylitis]. Varga E; Petró A; Jáger R; Varga L Orv Hetil; 2009 Oct; 150(43):2000-3. PubMed ID: 19812023 [TBL] [Abstract][Full Text] [Related]
37. One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study. Chimenti MS; Fonti GL; Conigliaro P; Sunzini F; Scrivo R; Navarini L; Triggianese P; Peluso G; Scolieri P; Caccavale R; Picchianti Diamanti A; De Martino E; Salemi S; Birra D; Altobelli A; Paroli M; Bruzzese V; Laganà B; Gremese E; Conti F; Afeltra A; Perricone R Expert Opin Biol Ther; 2020 Jul; 20(7):813-821. PubMed ID: 32401062 [TBL] [Abstract][Full Text] [Related]
38. Reply to eLetter by Feldtkeller et al. Sørensen J; Hetland ML Ann Rheum Dis; 2014 Dec; 73(12):e78. PubMed ID: 25281722 [No Abstract] [Full Text] [Related]
39. Inflammatory arthritis: an overview for primary care physicians. Brent LH Postgrad Med; 2009 Mar; 121(2):148-62. PubMed ID: 19332973 [TBL] [Abstract][Full Text] [Related]
40. In brief: new indications for secukinumab (Cosentyx). Med Lett Drugs Ther; 2016 Jun; 58(1496):76. PubMed ID: 27249098 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]